TY - JOUR T1 - PREVALENCE OF MOLECULAR AND SEROLOGICAL TESTS OF THE NEW CORONAVIRUS (SARS-CoV-2) IN CARLOS CHAGAS-SABIN LABORATORIES IN CUIABÁ JF - medRxiv DO - 10.1101/2020.10.26.20219683 SP - 2020.10.26.20219683 AU - Cristiane Coimbra de Paula AU - João Pedro Castoldo Passos AU - Walkiria Shimoya-Bittencour AU - Caroline Aquino Vieira de Lamare AU - Ruberlei Godinho de Oliveira Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219683.abstract N2 - BACKGROUND COVID-19, the disease caused by the new coronavirus (SARS-CoV-2), became a pandemic in 2020 with mortality rate of 2% and high transmissibility, which makes studies with an epidemiological profile essential.OBJECTIVES To characterize the population that performed the SARS-CoV-2 molecular and serological tests in Carlos Chagas-Sabin laboratories in Cuiabá.METHODS A retrospective cross-sectional study was carried out with all the samples collected from nasal swab tested by RT-PCR and serological for SARM-CoV-2 IgM / IgG from the population served between April and July 2020.FINDINGS In the analyzed period, 11,113 PCR-Covid-19 exams were registered. Of this total of cases, 3,912 (35.20%) tested positive, while 6,889 (61.90%) did not detect viral RNA and 312 (2.80%) of the visits resulted as undetermined. The peak of positive RT-PCR performed in July (n = 5878), with 35.65% (n = 2096). A total of 6,392 tests performed on SOROVID-19, with a peak of 1161 (18.16%) of the positive tests for SARS-CoV-2 in July.MAIN CONCLUSIONS Molecular positivity and serological tests, both peaked in July 2020, were mostly present in women aged 20-39, characterizing Cuiabá as the epicenter of the Midwest region in this period due to the high rate of transmissibility of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank Laboratorio Carlos Chagas-Sabin in Cuiaba, MT, Brazil for technical support durgin the analysis and Ethics committee to approval the project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of UNIVAG- Centro Universit&aacuterio under protocol number CAAE: 37320320.1.0000.5692. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional). It is the Principal Researchers responsibility to ensure that all researchers associated with this project are aware of the conditions of approval and which documents have been approved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a retrospective cross-sectional study with samples from the secondary database of Carlos Chagas Laboratory - Grupo Sabin, in Cuiab&aacute - MT, collected between April and July 2020. In order to verify the prevalence of molecular and serological tests for SARS-CoV-2, all samples from people seen in the laboratory of both sexes were included, without age restriction; and the reports of the molecular tests performed by qPCR-RT through the extraction of the genetic material of the nasal swab virus, as well as serological tests SOROVID-19 (IgM and IgG) for the detection of antibodies to SARS-CoV-2. Rapid IgG or IgM test data were excluded from the study. Data were expressed as absolute frequency and percentages with tabulation in Microsoft Excel. ER -